biomodal
PrivateLast Round
Series D
Nov 2, 2021
Total Funding Raised
$144.5M
Company Overview
biomodal operates in Healthcare & Life Sciences and is based in Cambridge. Its latest recorded funding round was a Series D round in November 2021.
biomodal is an omics-based life sciences technology and analytics company that develops multiomic sequencing solutions to capture genetic and epigenetic information from DNA samples.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Precision Medicine, Drug Discovery, Healthcare Analytics
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
biomodal Comparables
Compare biomodal with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Element Biosciences | 78% | |
| Watchmaker Genomics | 77% | |
| Illumina, Inc. | 71% |
For institutional investors. Book with your work email.
biomodal Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Nov 2, 2021 | ||||
| Grant | Jan 1, 2020 | ||||
| Series C | Apr 2, 2018 | ||||
| Series B | Mar 14, 2016 | ||||
| Series A | Oct 29, 2014 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
biomodal Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Temasek | Series D |
| GV | Series C, Series D, Series B |
| Syncona | Series A, Series B, Series C |
| European Commission | Grant |
| JIMCO | Series D |
| Sequoia Capital | Series B, Series C, Series D |
| DNA Capital | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 1, 2026
Launched duet +modC and duet evoC solutions.
- Nov 1, 2025
Filed complaint against Watchmaker Genomics, Inc. on November 1, 2025.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesAug 14, 2026
In Aug '26, Biomodal launches the duet mosaic family, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research that support early cancer detection; kits are available now in 8-, 24- and 96-reaction formats for standard short-read sequencing platforms.
For institutional investors. Book with your work email.
biomodal Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about biomodal's valuation, stock price, and market status.
Is biomodal a public or private company?
biomodal is a private company.
What is the current stock price of biomodal?
biomodal is a private company, so its shares have no public market price. Caplight tracks biomodal's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is biomodal worth (valuation)?
Valuation information for biomodal is not publicly available.
Can I buy biomodal stock?
biomodal shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was biomodal's last funding round?
biomodal's most recent funding round was Series D on November 2, 2021.
Who are the main investors in biomodal?
Key investors in biomodal include Temasek, GV, Ahren Innovation Capital, New Science Ventures.
Will biomodal IPO soon?
No public IPO plans have been announced for biomodal.
How can I track biomodal secondary market activity?
Caplight tracks bids, offers, and trades in biomodal's shares on secondary markets.